Walk into any small-town coffee shop or cafe in the Corn Belt right now and the mood is about as black as the coffee. Input costs are still stubbornly high, commodity prices are still soft and USDA says crop profit margins are running at their worst since the 2016 to 2020 stretch. Producers are once again tightening their belts.
Ironically, so are a lot of their customers — literally. About 1 in 8 American adults is now taking a GLP-1 drug like Ozempic, Wegovy or Mounjaro, and these medicines are so effective at suppressing appetite that clinical research shows users cutting their total calorie intake by 16% to 39%.
That’s not a wellness trend; that’s a pharmacological paradigm shift in how a big chunk of the country eats, and it’s already showing up in grocery store data.
So, here’s a question to ask as farmers sit in the tractor seat this spring: Does any of this upheaval of eating habits eventually change what crops farmers choose to grow? Not yet, but the early signals are worth understanding, especially if GLP-1 prescriptions continue to accelerate.
This isn’t a weather event. It’s a slow-moving shift in what Americans want to eat, and the food industry is already voting with its money.
What Grocery Data Actually Shows
Cornell University researchers published a study in December 2025 that tracked buying habits of roughly 150,000 U.S. households — not surveys about what people say they eat but ratherreal transaction data from Numerator, a market research firm. The findings should set off alarm bells up and down the food chain.
Within six months of starting a GLP-1 drug, households cut grocery spending by an average of 5.3%. Higher-income households dropped more than 8%. Restaurant and fast-food spending fell about 8%, too.
What they stopped buying is the important part. Savory snacks dropped roughly 10%. Sweet bakery items and cookies fell 7% to 11%. These are the calorie-dense, grab-it-off-the-shelf categories that GLP-1 drugs target most directly; they quiet the brain’s craving response to sugar and fat.
On the flip side, yogurt, fresh fruit and protein-forward items actually ticked up. Smaller portions, better ingredients, more protein. That’s the pattern.
Today, about 30 million Americans are on these drugs. That number is expected to climb as cheaper oral versions hit the market and insurance coverage expands. A share that size eating noticeably differently is a real market signal, even if it’s still working its way through the system.
Food Industry Is Already Changing Its Playbook
You don’t have to take anyone’s word for the trend; just watch what the major food companies are doing with their money.
Nestlé has launched an entirely new U.S. brand called Vital Pursuit — its first new brand in about 30 years. The brand is built specifically around the needs of GLP-1 users: high protein, high fiber, moderate calories. Conagra is putting “GLP-1 Friendly” badges on 26 of its Healthy Choice frozen meals.
PepsiCo is a more sobering example: The company reported five straight quarters of North American snack volume declines, closed several Frito-Lay plants and spent close to $3 billion buying a prebiotic soda brand and a grain-free snack company in a hard pivot toward what consumers actually want. On a recent investor call, PepsiCo’s leadership said the company now plans around the assumption that GLP-1 use will keep growing. That’s a big shift from where it was two years ago.
In restaurants, GLP-1 marketing is in high gear. Chipotle launched a high-protein menu last December featuring items with 46 g to 79 g of protein. It didn’t add a single new ingredient; it just repackaged what it already had for a consumer who now thinks about protein first.
What Does This Mean at the Farm Gate?
Right now, the GLP-1 shift is happening way upstream in consumers’ appetites and shopping carts. For that current to reach the farm, it has to travel through processors, ingredient buyers and food companies changing what ultimately shows up on grocery shelves and dinner plates.
That’s a long river with a lot of bends. Don’t expect such a shift to show up in this year’s corn basis or soybean meal price, but over the next five to 10 years, what gets grown and what commands a premium could look different.
The rough breakdown: Crops and inputs that go into calorie-dense snack foods, sugary beverages and alcohol face the clearest headwinds. High-fructose corn syrup, malting barley for beer and soft wheat for cookies and pastries are the most directly exposed demand channels — and some, like malting barley, are already in structural decline for other reasons. GLP-1 adoption accelerates a trend that was already moving.
The other side of the ledger looks better. Dairy proteins — think whey, Greek yogurt, cottage cheese — are actually seeing a rise in demand. Poultry and eggs fit the protein-first eating pattern that GLP-1 guidelines recommend. Pulses like lentils, dry peas and chickpeas are a quiet beneficiary; rising ingredient demand for plant protein and fiber in reformulated foods lines up neatly with the rotation benefits these crops already offer on northern Plains farms. Soy meal benefits if poultry expands, and the renewable diesel market provides a cushion for soy oil even as food-channel demand softens.
Beef is genuinely mixed. GLP-1 users eat less overall, which puts some pressure on volume. But the shift toward higher-quality, nutrient-dense protein could actually support beef’s per-unit value even if total tonnage slips.
3 Scenarios Worth Knowing
Nobody knows how widespread GLP-1 use may propagate throughout the U.S. population. The biggest wild card is how many people actually stay on these drugs long-term.
Real-world data shows 30% to 65% of users discontinue within a year, mostly because of cost. However, even with such uncertainties, it is plausible that within a decade nearly 30% of the adults in the country could be on some form of GLP-1.
The following table shows the impact on the demand of three different food categories based on various ranges of GLP-1 adoption ranging from 10% to 30%. These are illustrative ranges only, not forecasts. That’s why the range of each scenario is wide. As oral versions get cheaper and coverage expands, the upper end of these ranges becomes more plausible.
Slow But Consequential Shift
The numbers are illustrative, but the direction isn’t in doubt. The last time a single policy decision reshuffled commodity demand at this scale was the Renewable Fuel Standard of 2005. Within a decade, corn ethanol went from a niche market to consuming roughly 40% of the U.S. corn crop. Producers who saw it coming early pivoted by shifting acres, building infrastructure and locking in contracts. Those who ignored it were left scrambling to catch up.
The GLP-1 shift won’t arrive with a single legislative thunderclap — it’s a slower burn — but the destination looks just as consequential. The U.S. food system has spent a century optimizing for calories per acre. These drugs are the first force in a generation capable of tilting that equation toward protein and nutrition per acre instead.
What should farmers actually do right now? First, start looking at what they produce through the lens of protein. In protein-tilted diets, soybeans and meat beat out corn and wheat.
If they’re a dairy or poultry producer, protein is the wind at their back. Also, consider diversifying into pulse crops (lentils, dry peas, chickpeas) that deliver rotation value and align with where ingredient demand is heading.
Food companies have already placed their bets. The biggest unanswered question is what changes back at the farm gate — and when.
Producers asking that question today will be the ones with options when the answer arrives.
Steve Cubbage is a precision ag consultant and farmer from Nevada, Mo. He is the founder of Longitude 94, an agriculture sustainability and technology consulting business.
